Sartorius Stedim: completes acquisition of Polyplus
(CercleFinance.com) - Having received the necessary regulatory approvals, Sartorius Stedim Biotech announces that it has completed the acquisition of the French company Polyplus, a transaction announced at the end of March for almost E2.
Polyplus, which employs some 270 people, supplies innovative technologies for cell and gene therapy. Its plasmids and transfection reagents are key components in the manufacture of viral vectors.
Headquartered in Strasbourg, with sites in France, Belgium, the US and China, the company is expected to generate sales in the high tens of millions of euros by 2023, with a very high EBITDA margin, the company said.
Copyright (c) 2023 CercleFinance.com. All rights reserved.